Literature DB >> 4694345

Formalin-inactivated Venezuelan equine encephalomyelitis (Trinidad strain) vaccine produced in rolling-bottle cultures of chicken embryo cells.

F E Cole, S W May, D M Robinson.   

Abstract

Formalin-inactivated Venezuelan equine encephalomyelitis vaccine was prepared from virus grown in rolling-bottle cultures of chicken embryo cells. Trinidad strain virus was propagated in these cultures with a maintenance medium consisting of serum-free medium 199 containing 0.25% human serum albumin (USP) and antibiotics. Manipulation of multiplicity of inoculum (0.06 to 0.00006) and maintenance medium volume (100 to 300 ml) resulted in high-titered virus yields and only moderate cell destruction when fluids from infected cultures were harvested at 18 to 24 hr. The virus was inactivated at 37 C by 0.05% Formalin within 8 to 10 hr and with 0.1% Formalin within 6 to 8 hr. Single dose, antigen extinction tests in mice performed with 30 small-scale vaccine lots showed excellent potency at either Formalin concentration with inactivation periods ranging from 24 to 96 hr.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4694345      PMCID: PMC380783          DOI: 10.1128/am.25.2.262-265.1973

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  14 in total

1.  USE OF AN ATTENUATED STRAIN OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS FOR IMMUNIZATION IN MAN.

Authors:  R W MCKINNEY; T O BERGE; W D SAWYER; W D TIGERTT; D CROZIER
Journal:  Am J Trop Med Hyg       Date:  1963-07       Impact factor: 2.345

2.  Japanese B encephalitis virus vaccines from tissue culture. VII. Formalin inactivated Nakayama strain vaccine.

Authors:  M A Darwish; W M Hammon
Journal:  Proc Soc Exp Biol Med       Date:  1966-07

3.  Inactivated eastern equine encephalomyelitis vaccines prepared in monolayer and concentrated suspension chick embryo cultures.

Authors:  A White; S Berman; J P Lowenthal
Journal:  Appl Microbiol       Date:  1971-11

4.  Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serological evaluation in man.

Authors:  P J Bartelloni; R W McKinney; F M Calia; H H Ramsburg; F E Cole
Journal:  Am J Trop Med Hyg       Date:  1971-01       Impact factor: 2.345

5.  An inactivated eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. II. Clinical and serologic responses in man.

Authors:  P J Bartelloni; R W McKinney; T P Duffy; F E Cole
Journal:  Am J Trop Med Hyg       Date:  1970-01       Impact factor: 2.345

6.  Use of hamsters of potency assay of Eastern and Western equine encephalitis vaccines.

Authors:  F E Cole; R W McKinney
Journal:  Appl Microbiol       Date:  1969-06

7.  Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man.

Authors:  A C Alevizatos; R W McKinney; R D Feigin
Journal:  Am J Trop Med Hyg       Date:  1967-11       Impact factor: 2.345

8.  Inactivated eastern equine encephalomyelitis vaccine propagated in rolling-bottle cultures of chick embryo cells.

Authors:  F E Cole
Journal:  Appl Microbiol       Date:  1971-11

9.  Gamma-irradiated Venezuelan equine encephalitis vaccines.

Authors:  M Reitman; H R Tribble; L Green
Journal:  Appl Microbiol       Date:  1970-05

10.  Immunogenicity of purified venezuelan equine encephalitis virus inactivated by ionizing radiation.

Authors:  J Gruber
Journal:  Infect Immun       Date:  1971-04       Impact factor: 3.441

View more
  8 in total

1.  Improved method for production of attenuated Venezuelan equine encephalomyelitis (TC-83 strain) vaccine.

Authors:  F E Cole; C E Pedersen; D M Robinson; G A Eddy
Journal:  J Clin Microbiol       Date:  1976-04       Impact factor: 5.948

2.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Inactivated Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus.

Authors:  F E Cole; S W May; G A Eddy
Journal:  Appl Microbiol       Date:  1974-01

4.  A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Authors:  Lesley C Dupuy; Michelle J Richards; Barry Ellefsen; Lillian Chau; Alain Luxembourg; Drew Hannaman; Brian D Livingston; Connie S Schmaljohn
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

5.  Effects of antigen-antibody complexes on the primary immune response in Rhesus monkeys.

Authors:  W E Houston; C E Pedersen; F E Cole; R O Spertzel
Journal:  Infect Immun       Date:  1974-09       Impact factor: 3.441

Review 6.  Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.

Authors:  Anuj Sharma; Barbara Knollmann-Ritschel
Journal:  Viruses       Date:  2019-02-18       Impact factor: 5.048

7.  A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge.

Authors:  John J Suschak; Sandra L Bixler; Catherine V Badger; Kristin W Spik; Steven A Kwilas; Franco D Rossi; Nancy Twenhafel; Melissa L Adams; Charles J Shoemaker; Erin Spiegel; Jay W Hooper
Journal:  NPJ Vaccines       Date:  2022-04-22       Impact factor: 9.399

8.  A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.

Authors:  Lesley C Dupuy; Michelle J Richards; Brian D Livingston; Drew Hannaman; Connie S Schmaljohn
Journal:  J Immunol Res       Date:  2018-06-03       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.